Screener
Trevi Therapeutics, Inc. TRVI Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Trevi Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Trevi Therapeutics, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-206390
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development | $9,941 | $7,811 |
| General and administrative | 4,971 | 3,659 |
| Total operating expenses | 14,912 | 11,470 |
| Loss from operations | (14,912) | (11,470) |
| Other income (expense): | ||
| Interest income, net | 1,696 | 1,125 |
| Other income (expense), net | 4 | (6) |
| Total other income, net | 1,700 | 1,119 |
Item 1. Condensed Consolidated Financial Statements.
FAQ
- What is Trevi Therapeutics, Inc.'s operating income?
- Trevi Therapeutics, Inc. (TRVI) reported operating income of -$14.91M in Q1 2026.
- How has Trevi Therapeutics, Inc.'s operating income changed year-over-year?
- Trevi Therapeutics, Inc.'s operating income decreased by 30.0% year-over-year, from -$11.47M to -$14.91M.
- What is the long-term trend for Trevi Therapeutics, Inc.'s operating income?
- Over 4 years (2021 to 2025), Trevi Therapeutics, Inc.'s operating income has grown at a 11.0% compound annual growth rate (CAGR), from -$32.48M to -$49.33M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Trevi Therapeutics, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude